Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma‐1 receptor antagonist in three randomized phase I studies

Abstract

S1RA exhibited an acceptable safety, tolerability, pharmacodynamic and pharmacokinetic profile in healthy subjects over the dose range studied.